Synthetic organic

Product Describtion:CITCO is an imidazothiazole derivative. It stimulates human constitutive androstane receptor (CAR) nuclear translocation.Product Application：CITCO has been used for the activation of mouse constitutive androstane receptor (CAR)

Product Describtion:CITCO is an imidazothiazole derivative. It stimulates human constitutive androstane receptor (CAR) nuclear translocation.Product Application：CITCO has been used for the activation of mouse constitutive androstane receptor (CAR)

Product Describtion:CITCO is an imidazothiazole derivative. It stimulates human constitutive androstane receptor (CAR) nuclear translocation.Product Application：CITCO has been used for the activation of mouse constitutive androstane receptor (CAR)

Product Describtion:CITCO is an imidazothiazole derivative. It stimulates human constitutive androstane receptor (CAR) nuclear translocation.Product Application：CITCO has been used for the activation of mouse constitutive androstane receptor (CAR)

Product Describtion:CITCO is an imidazothiazole derivative. It stimulates human constitutive androstane receptor (CAR) nuclear translocation.Product Application：CITCO has been used for the activation of mouse constitutive androstane receptor (CAR)

Product Describtion:CITCO is an imidazothiazole derivative. It stimulates human constitutive androstane receptor (CAR) nuclear translocation.Product Application：CITCO has been used for the activation of mouse constitutive androstane receptor (CAR)

CJ-42794 (CJ-042794) is a selective antagonist of prostaglandin E receptor subtype 4 (EP4). It inhibits [3H]-PGE2 binding to the human EP4 receptor (a mean pKi: 8.5). CJ-42794 is a binding affinity that was at least 200-fold more selective for the

CJ-42794 (CJ-042794) is a selective antagonist of prostaglandin E receptor subtype 4 (EP4). It inhibits [3H]-PGE2 binding to the human EP4 receptor (a mean pKi: 8.5). CJ-42794 is a binding affinity that was at least 200-fold more selective for the

CJ-42794 (CJ-042794) is a selective antagonist of prostaglandin E receptor subtype 4 (EP4). It inhibits [3H]-PGE2 binding to the human EP4 receptor (a mean pKi: 8.5). CJ-42794 is a binding affinity that was at least 200-fold more selective for the

CJ-42794 (CJ-042794) is a selective antagonist of prostaglandin E receptor subtype 4 (EP4). It inhibits [3H]-PGE2 binding to the human EP4 receptor (a mean pKi: 8.5). CJ-42794 is a binding affinity that was at least 200-fold more selective for the

CJ-42794 (CJ-042794) is a selective antagonist of prostaglandin E receptor subtype 4 (EP4). It inhibits [3H]-PGE2 binding to the human EP4 receptor (a mean pKi: 8.5). CJ-42794 is a binding affinity that was at least 200-fold more selective for the

CJ-42794 (CJ-042794) is a selective antagonist of prostaglandin E receptor subtype 4 (EP4). It inhibits [3H]-PGE2 binding to the human EP4 receptor (a mean pKi: 8.5). CJ-42794 is a binding affinity that was at least 200-fold more selective for the